Saturday 17 October 2026
Export ORKA’s income statement to Excel — free account
Oruka Therapeutics, Inc.
ORKA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 19.6% and free cash flow fell 43.0%, each against the same quarter a year earlier.
71.93
1.94
−2.63%
Follow ORKA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(25.92%) | (24.86%) | (27.50%) | (18.30%) | |
| (23.11%) | (23.84%) | (26.37%) | (17.76%) | ||
ROIC |
(55.54%) | (56.55%) | (85.17%) | (40.22%) | |
Return on Tangible Assets |
(31.90%) | (32.07%) | (30.68%) | (15.42%) | |
Free Cash Flow per Share |
(1.92) | (1.94) | (1.65) | (1.61) | |
Free Cash Flow |
(84.60) | (88.42) | (91.19) | (101.15) | |
Capital Expenditures |
(0.16) | (0.21) | (0.27) | (0.23) | |
| Other line items | |||||
Cash ROIC |
(10.12%) | (10.93%) | (10.41%) | (5.09%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.79 | 0.84 | 0.78 | 0.76 | |
Depreciation/Fixed assets |
(25.75) | (17.08) | (11.14) | (10.80) | |
Capex/Depreciation |
0.03 | 0.04 | 0.08 | 0.08 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.92) | (1.93) | (1.65) | (1.61) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates